Free AccessMartín M. · Vallejo C. · López-Campos F. · Quereda C. · Muñoz T. · Sánchez-Conde M. · Dominguez J.A. · Soriano C. · Martín M. · Suárez-Carantoña C. · Muriel A. · Garrido P. · Acero J. · Alvarez-Diaz A. · de la Pinta C. · Martínez-García L. · Hernánz R. · Fernández E. · Alarza M. · Hervás A. · Sancho S.
Introduction: Cancer patients are more susceptible to infections and infection can be more severe than in patients without cancer diagnosis. We conducted this retrospective study in patients admitted for SARS-CoV-2 infection in order to find differences in inflammatory markers and mortality in cancer patients compared to others. Methods: We reviewed the electronic records of patients admitted for SARS-CoV-2 infection confirmed by PCR from March to September 2020. Data on socio-demographics, comorbidities, inflammatory makers and cancer-related features were analysed. Results: 2,772 patients were admitted for SARS-CoV-2, to the Hospital Universitario Ramón y Cajal in Madrid during this period. Of these, 2597 (91%) had no history of neoplastic disease, 164 (5.9%) patients had a prior history of cancer but were not undergoing oncological treatment at the time of infection, and 81 (2.9%) were in active treatment. Mortality in patients without a history of cancer was 19.5%, 28.6% for patients with a prior history of cancer and 34% in patients with active cancer treatment. Patients in active oncology treatment with the highest mortality rate, were those diagnosed with lung cancer (OR 5.6 95% CI 2.2-14.1). In the multivariate study active oncological treatment (OR 2.259 95% IC 1.35-3.77) and chemotherapy treatment (OR 3.624 95% IC 1.17-11.17), were statistically significant factors for the risk of death for the whole group and for the group with active oncological treatment, respectively. Conclusion: Cancer patients on active systemic treatment have an increased risk of mortality after SARS-CoV-2 infection, especially with lung cancer or chemotherapy treatment.
S. Karger AG, BaselArticle / Publication Details Copyright / Drug Dosage / Disclaimer Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.